Valrubicin
Valrubicin, Valstar (valrubicin) is a small molecule pharmaceutical. Valrubicin was first approved as Valstar preservative free on 1998-09-25. It is used to treat urinary bladder neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Valrubicin, Valstar
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| valrubicin intravesical solution | ANDA | 2022-06-30 |
| valstar | New Drug Application | 2024-10-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| urinary bladder neoplasms | — | D001749 | C67 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9357 | Injection, valrubicin, intravesical, 200 mg |
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 1 | 1 | 2 | — | 1 | 4 |
| Carcinoma in situ | D002278 | — | D09.9 | — | 1 | 2 | — | 1 | 3 |
| Transitional cell carcinoma | D002295 | — | — | 1 | — | 1 | — | — | 2 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | 1 | — | 1 | 2 |
| Non-muscle invasive bladder neoplasms | D000093284 | — | — | — | — | 1 | — | 1 | 2 |
| Recurrence | D012008 | — | — | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urologic neoplasms | D014571 | — | C64-C68 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Valrubicin |
| INN | valrubicin |
| Description | Valrubicin is an anthracycline and a trifluoroacetamide. |
| Classification | Small molecule |
| Drug class | antineoplastic antibiotics (daunorubicin type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC(=O)OCC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(OC)cccc1C3=O |
Identifiers
| PDB | — |
| CAS-ID | 56124-62-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1096885 |
| ChEBI ID | — |
| PubChem CID | 454216 |
| DrugBank | DB00385 |
| UNII ID | 2C6NUM6878 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,306 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
173 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use